Gufic Biosciences Ltd

Gufic Biosciences Ltd

$GUFICBIOPharmaceuticalsNSEBSE

Gufic Biosciences Ltd (GUFICBIO) last traded at ₹416, a market capitalisation of ₹4,168 crore, on a P/E of 56.7. Over the past 52 weeks the stock has ranged between ₹268 and ₹448. Gufic Biosciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹261 crore and net profit of ₹22 crore. Gufic Biosciences Ltd’s annual general meeting is scheduled for 4 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Gufic Biosciences Ltd share price and key metrics

Current price
₹416
Market cap
₹4,168 cr
Stock P/E
56.7
Book value
₹66.3
ROE
10.1%
ROCE
12.3%
Dividend yield
0.02%
52w high / low
448/268

Metrics as of 25 Aug 2026. Not real time.

Gufic Biosciences Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹261 cr, up 16.5% from ₹224 cr a year earlier. Net profit was ₹22 cr, up 69.2% year on year.

Gufic Biosciences Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales204208205224237231252261
Expenses166174179190199198205214
Operating profit3934263338334747
OPM %19%16%13%15%16%14%19%18%
Other income020121-10
Interest558910899
Depreciation45888888
Profit before tax2926111723182930
Tax %26%26%27%24%26%30%24%26%
Net profit221981317122222
EPS (₹)2.171.930.771.301.681.242.182.22

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Gufic Biosciences Ltd annual results

Gufic Biosciences Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2024Mar 2025Mar 2026TTM
Sales807820944981
Operating profit150136151165
OPM %19%17%16%17%
Net profit86706473
EPS (₹)8.596.956.407.32

TTM is the trailing twelve months to the most recent quarter.

Gufic Biosciences Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
%
3 Years
%
TTM
17%
Compounded Profit Growth
10 Years
%
5 Years
%
3 Years
%
TTM
19%
Stock Price CAGR
10 Years
27%
5 Years
18%
3 Years
14%
1 Year
10%
Return on Equity
10 Years
%
5 Years
%
3 Years
13%
Last Year
10%

Gufic Biosciences Ltd shareholding pattern

Promoters held 72.50% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.47% and DIIs 3.67%.

Gufic Biosciences Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters72.51%72.51%72.51%72.51%72.50%72.50%72.50%72.50%
FIIs0.23%0.30%0.31%0.32%0.33%0.44%0.42%0.47%
DIIs2.51%2.99%3.39%3.38%3.66%3.74%3.83%3.67%
Public24.75%24.20%23.79%23.81%23.51%23.30%23.23%23.36%
No. of shareholders32,82533,29931,84431,87631,42030,36229,22329,753

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Gufic Biosciences Ltd’s AGM?

Gufic Biosciences Ltd’s annual general meeting is scheduled for 4 Sept 2026.

  • AGM42nd AGM, adoption of financial statements, declaration of final dividend, and re-appointment of directors

See the full results calendar for every Indian company reporting in the next 30 days.

Gufic Biosciences Ltd corporate filings

  • Written Transcript of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewithCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited reported a strong Q1 FY27 performance with revenue from…

    Read the full analysis
  • Newspaper advertisement regarding Special Window for re-lodgement of transfer and dematerialization of physical shares is attached herewithCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences has published a newspaper advertisement regarding a special window for…

    Read the full analysis
  • Intimation of Audio Recording of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewithCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited has formally uploaded the audio recording of its earnings…

    Read the full analysis
  • Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 is attached herewith.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited has released its unaudited standalone and consolidated…

    Read the full analysis
  • Investor Presentation for the Quarter ended June 30, 2026 is attached herewithCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited reported a strong Q1 FY2027 performance with total revenue of…

    Read the full analysis
  • Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital is attached herewith.Company Updatemedium impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited has announced the board's approval to incorporate a new…

    Read the full analysis
  • Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 is attached herewith.Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited reported standalone revenue of 260.82 crore for the quarter…

    Read the full analysis
  • Newspaper Advertisement - Notice of 42nd Annual General Meeting of the Company and evoting details is attached herewith.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Ltd has issued a newspaper advertisement regarding the notice of its…

    Read the full analysis
  • Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, is attached herewithOtherslow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences has submitted its Business Responsibility and Sustainability Report…

    Read the full analysis
  • Annual Report for the Financial Year 2025-2026 alongwith Notice of 42nd Annual General Meeting is attached herewith.Otherslow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences has filed its Annual Report for the financial year 2025-2026 along with…

    Read the full analysis
  • Intimation of 42nd Annual General Meeting, is attached herewithAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited has scheduled its 42nd Annual General Meeting for September 4…

    Read the full analysis
  • Intimation of Earnings Conference Call scheduled to be held on August 17, 2026 is attached herewithCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited has announced an earnings conference call to discuss its…

    Read the full analysis
  • Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Limited has formally intimated the stock exchanges regarding a Board of…

    Read the full analysis
  • Newspaper Advertisement - Notice of the 42nd Annual General Meeting of the Company is attached herewithCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gufic Biosciences Ltd has issued a newspaper advertisement regarding the notice of its…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Gufic Biosciences Ltd

Cruxal reads every Gufic Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Gufic Biosciences Ltd (GUFICBIO) Results, Financials & Share Price | Cruxal